Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Cash Per Share 1 year YoY Change (%) for the year ending April 30, 2023: 60.57%

Kalvista Pharmaceuticals Inc Cash Per Share 1 year YoY Change (%) is 60.57% for the year ending April 30, 2023, a 215.14% change year over year. The cash per share represents the amount of cash available to each outstanding share of common stock. It is calculated by dividing the total cash by the weighted average number of shares outstanding. This metric provides insight into the cash position of the company on a per-share basis and can be used to evaluate the company's liquidity and ability to distribute cash to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Kalvista Pharmaceuticals Inc Cash Per Share for the year ending April 30, 2022 was 1.26, a -52.61% change year over year.
Kalvista Pharmaceuticals Inc Cash Per Share for the year ending April 30, 2021 was 2.65, a 197.84% change year over year.
Kalvista Pharmaceuticals Inc Cash Per Share for the year ending April 30, 2020 was 0.89, a -58.08% change year over year.
Kalvista Pharmaceuticals Inc Cash Per Share for the year ending April 30, 2019 was 2.12, a -57.09% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends